Kineta, Inc. Stock Price, News & Analysis

Kineta, Inc. (Nasdaq: KA) has successfully completed a registered direct offering for 1,425,179 shares of its common stock at a price of $4.21 per share, generating approximately $6 million in gross proceeds. The offering was conducted under a previously filed shelf registration statement and includes unregistered warrants to purchase up to the same number of shares at an exercise price of $4.08, valid for 5.5 years. The company intends to use the net proceeds for working capital. H.C. Wainwright & Co. acted as the exclusive placement agent.

This offering aligns with Kineta's strategic focus on developing innovative immunotherapies for cancer treatment, specifically targeting issues of immune resistance.

On April 20, 2023, Kineta, Inc. (Nasdaq: KA) announced a registered direct offering of 1,425,179 shares of common stock at $4.21 per share, resulting in gross proceeds of approximately $6 million. This offering includes pre-funded warrants and warrants to purchase additional shares at $4.08 each, exercisable for five years. The transaction is set to close around April 24, 2023, subject to standard closing conditions. The company plans to utilize the proceeds for working capital purposes. H.C. Wainwright & Co. serves as the exclusive placement agent for this offering, which is made under a previously effective shelf registration statement. Kineta is focused on developing innovative immunotherapies targeting cancer immune resistance, with its lead candidate, KVA12123, aimed at addressing various cancer types.

Kineta, Inc. (Nasdaq: KA) announced significant updates on their KVA12123 Phase 1/2 clinical trial during the AACR Annual Meeting 2023, highlighting new VISTA biomarker data. The presentation, made by Dr. Thierry Guillaudeux, demonstrated the role of VISTA as a potential immuno-oncology target across various cancers, including non-small cell lung cancer and colorectal cancer. Key findings revealed VISTA expression in tumor-infiltrating immune cells and elevated levels of soluble VISTA in patient serum samples. The ongoing trial aims to collect tissue and serum samples from patients prior to KVA12123 treatment to assess the clinical response related to VISTA expression. These findings open avenues for optimizing treatment and identifying effective biomarkers. For further details, the poster is available on Kineta's website.

Kineta, Inc. (Nasdaq: KA) has announced the dosing of the first patient in a Phase 1/2 clinical trial for KVA12123, a VISTA blocking immunotherapy aimed at tackling immunosuppression in the tumor microenvironment in patients with advanced solid tumors. This trial will evaluate KVA12123 alone and in combination with pembrolizumab, with initial results expected by the end of 2023. The therapy targets cancers where VISTA is highly expressed, including colorectal and non-small cell lung cancers, which correlate with poor patient outcomes. The study includes dose escalation and expansion phases to determine safety, tolerability, and tumor response.

This first-in-human trial represents a crucial milestone for Kineta, addressing an urgent need for new cancer therapies.

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology firm, announced that its CEO, Shawn Iadonato, Ph.D., will present at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, from 12:45 to 1:25 PM ET. Virtual one-on-one meetings will also be available. Kineta is dedicated to developing innovative cancer immunotherapies, including KVA12123, a monoclonal antibody aimed at overcoming immunosuppression in tumors. This therapy targets a significant unmet medical need across various cancer types. The presentation can be accessed later through the company's website.

Kineta (Nasdaq: KA) announced the opening of a Phase 1/2 clinical study for KVA12123, an anti-VISTA monoclonal antibody targeting advanced solid tumors. The FDA has accepted the IND application for this immunotherapy, with initial data expected by the end of 2023. The company completed a reverse merger with Yumanity Therapeutics, trading under the new ticker KA since December 19, 2022. Financially, for the year ending December 31, 2022, Kineta reported a net loss of $63.4 million ($12.87 per share), largely due to increased research, operational expenses, and higher interest costs, despite cash reserves of $13.1 million, expected to fund operations for at least 12 months.

Kineta, a clinical-stage biotechnology company (Nasdaq: KA), announced its participation in the AACR Annual Meeting 2023 in Orlando from April 14-19. The Chief Scientific Officer, Thierry Guillaudeux, will present a poster on preclinical data regarding VISTA expression as a potential biomarker in advanced solid tumors. The poster titled 'VISTA expression in patients with advanced solid tumors: A potential biomarker in VISTA-101 clinical trial' will feature during the session on Biomarkers of Therapeutic Benefit on April 16, from 1:30 PM to 5:00 PM ET, at Section 39.

Kineta focuses on innovative immunotherapies targeting cancer immune resistance, with KVA12123 as a leading candidate addressing immunosuppression in the tumor microenvironment.

Kinetica, Inc. (Nasdaq: KA), a clinical-stage biotechnology company, announced that CEO Shawn Iadonato will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference, taking place virtually from March 13-15, 2023. The presentation is scheduled for March 13, 2023, from 9:20-9:50 A.M. Eastern Time. Attendees can access the webcast under Events & Presentations on the company's website. Kineta focuses on developing innovative immunotherapies like KVA12123 to combat cancer immune resistance, targeting various cancer types including NSCLC and colorectal cancer.

Kineta, a clinical-stage biotechnology company (Nasdaq: KA), will host a virtual Key Opinion Leader event on March 20, 2023, at 10:00 AM ET. The session will focus on VISTA as an immuno-oncology target, featuring insights from experts Michael A. Curran, PhD, and Patricia LoRusso, DO. Discussions will address the challenges of immunosuppression in tumors and include an update on Kineta's lead program, KVA12123, a novel anti-VISTA monoclonal antibody currently in a Phase 1/Phase 2 study. Participants can engage in a live Q&A following the presentations. Interested individuals can register for the event through Kineta's website.